Sort
40,608 grants matching “prostate cancer”
Interaction of germline and somatic changes in PCa progression
$409,792Wennuan Liu · Wake Forest University Health Sciences · R01 · FY2009 · CA
Radiation induced bystander effects in radium-223 therapy
$409,785Roger W Howell · Rbhs-New Jersey Medical School · R01 · FY2016 · CA
Cancer Nanotechnology in Imaging and Radiotherapy
$409,771Gayle E Woloschak · Northwestern University At Chicago · R25 · FY2013 · CA
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
$409,727Davide Ruggero · University Of California, San Francisco · R01 · FY2013 · CA
ANDROGEN INDEPENDENT PROSTATE CANCER:A TRANSGENIC MODEL
$409,666Norman Michael Greenberg · Fred Hutchinson Cancer Research Center · R01 · FY2006 · CA
PHASE I STUDIES OF ANTICANCER AGENTS
$409,660Sloan-Kettering Institute For Cancer Res · U01 · FY2000 · CA
Molecular Analysis of Steroid Hormone Receptors with X-ray Crystallography
$409,659Kendall W Nettles · Scripps Research Institute, The · R33 · FY2010 · CA
Multiphoton Detection of Cancer
$409,620Warren R Zipfel · Cornell University · R01 · FY2009 · CA
CCCWFU RESEARCH BASE GRANT
$409,573Wake Forest University Health Sciences · U10 · FY2000 · CA
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
$409,560Paul Robustelli · Dartmouth College · R35 · FY2024 · GM
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
$409,560Paul Robustelli · Dartmouth College · R35 · FY2023 · GM
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
$409,560Paul Robustelli · Dartmouth College · R35 · FY2022 · GM
Characterizing the binding mechanisms of castration-resistant prostate cancer therapeutics to the intrinsically disordered N-terminal domain of the androgen receptor
$409,560Paul Robustelli · Dartmouth College · R35 · FY2025 · GM
Mechanisms of prostate cancer prevention by Korean Angelica
$409,525Junxuan Lu · Texas Tech University Health Scis Center · R01 · FY2014 · AT
Mechanisms of prostate cancer prevention by Korean Angelica
$409,525Junxuan Lu · Texas Tech University Health Scis Center · R01 · FY2013 · AT
FACILITATING DISCOVERY THROUGH A HUMAN PROSTATE TISSUE R
$409,514Medical College Of Wisconsin · U01 · FY2000 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$409,513Daniel George Haller · University Of Pennsylvania · U10 · FY2008 · CA
AUTOPHAGY SIGNALING IN PROSTATE CANCER: IDENTIFICATION OF A NOVEL PHOSPHATASE
$409,500Van Andel Institute Graduate School · · FY2009 · Department of the Army
T-PHARMACYTES FOR PROSTATE CANCER IMMUNOTHERAPY
$409,464Massachusetts Institute Of Technology · · FY2010 · Department of the Army
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer
$409,463Li Jia · Brigham And Women'S Hospital · R01 · FY2021 · CA
MMS22L loss and PARP inhibition in prostate cancer
$409,463Li Jia · Brigham And Women'S Hospital · R01 · FY2025 · CA
MMS22L loss and PARP inhibition in prostate cancer
$409,463Li Jia · Brigham And Women'S Hospital · R01 · FY2023 · CA
Androgen receptor pathway inhibition through targeting PARP-2 in castration-resistant prostate cancer
$409,463Li Jia · Brigham And Women'S Hospital · R01 · FY2025 · CA
Estimating and Mitigating Thyroid Cancer Overdiagnosis: A Mathematical Modeling Approach
$409,405David O. Francis · University Of Wisconsin-Madison · R01 · FY2024 · CA
Advanced Tools for Reconstructing Population History
$409,401David Emil Reich · Harvard Medical School · R01 · FY2016 · GM